CN104321074B - 生长抑素类似物与11β‑羟化酶抑制剂的组合 - Google Patents

生长抑素类似物与11β‑羟化酶抑制剂的组合 Download PDF

Info

Publication number
CN104321074B
CN104321074B CN201380027076.7A CN201380027076A CN104321074B CN 104321074 B CN104321074 B CN 104321074B CN 201380027076 A CN201380027076 A CN 201380027076A CN 104321074 B CN104321074 B CN 104321074B
Authority
CN
China
Prior art keywords
combination
cushing
compound
patients
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380027076.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104321074A (zh
Inventor
G·H·格里克
H·A·施密德
鲁托密斯基 M·R·马尔多纳多
L·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104321074A publication Critical patent/CN104321074A/zh
Application granted granted Critical
Publication of CN104321074B publication Critical patent/CN104321074B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380027076.7A 2012-04-12 2013-04-10 生长抑素类似物与11β‑羟化酶抑制剂的组合 Active CN104321074B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
US61/623,117 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
CN104321074A CN104321074A (zh) 2015-01-28
CN104321074B true CN104321074B (zh) 2017-09-08

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380027076.7A Active CN104321074B (zh) 2012-04-12 2013-04-10 生长抑素类似物与11β‑羟化酶抑制剂的组合

Country Status (13)

Country Link
US (1) US9333234B2 (enExample)
EP (1) EP2836228B1 (enExample)
JP (1) JP6383352B2 (enExample)
KR (1) KR102136214B1 (enExample)
CN (1) CN104321074B (enExample)
AU (1) AU2013246908B2 (enExample)
BR (1) BR112014025058B1 (enExample)
CA (1) CA2869442C (enExample)
ES (1) ES2980806T3 (enExample)
IN (1) IN2014DN09240A (enExample)
MX (1) MX362533B (enExample)
RU (1) RU2663455C2 (enExample)
WO (1) WO2013153129A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102711916B (zh) * 2010-01-14 2015-09-02 诺华股份有限公司 肾上腺激素调节剂的用途
SG11201610227TA (en) * 2014-07-07 2017-01-27 Novartis Ag Pharmaceutical dosage forms
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
EP3405101B1 (en) * 2016-01-19 2020-12-23 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334742A (zh) * 1998-07-30 2002-02-06 研究及应用科学协会股份有限公司 促生长素抑制素类似物兰瑞肽的应用方法
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081499A2 (en) * 2001-04-09 2002-10-17 The Administrators Of The Tulane Educational Fund Somatostatin agonists
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
EP2507234B1 (en) * 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
WO2013131879A1 (en) * 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334742A (zh) * 1998-07-30 2002-02-06 研究及应用科学协会股份有限公司 促生长素抑制素类似物兰瑞肽的应用方法
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial;M. Boscaro et al.;《J Clin Endocrinol Metab》;20090131;第94卷(第1期);摘要 *

Also Published As

Publication number Publication date
CA2869442C (en) 2020-09-08
MX2014012321A (es) 2015-09-24
BR112014025058A2 (enExample) 2017-06-20
ES2980806T3 (es) 2024-10-03
RU2014145351A (ru) 2016-06-10
EP2836228B1 (en) 2024-03-20
CA2869442A1 (en) 2013-10-17
BR112014025058B1 (pt) 2022-07-12
US20150087588A1 (en) 2015-03-26
KR102136214B1 (ko) 2020-07-22
WO2013153129A1 (en) 2013-10-17
JP2015512923A (ja) 2015-04-30
CN104321074A (zh) 2015-01-28
EP2836228A1 (en) 2015-02-18
US9333234B2 (en) 2016-05-10
AU2013246908B2 (en) 2016-06-30
RU2663455C2 (ru) 2018-08-06
JP6383352B2 (ja) 2018-08-29
IN2014DN09240A (enExample) 2015-07-10
AU2013246908A1 (en) 2014-10-23
KR20150004831A (ko) 2015-01-13
MX362533B (es) 2019-01-23

Similar Documents

Publication Publication Date Title
Schally et al. Actions and potential therapeutic applications of growth hormone–releasing hormone agonists
EP3197429B1 (en) Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
JP2025114753A (ja) 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ
DeBoer Emergence of ghrelin as a treatment for cachexia syndromes
BR112013018679B1 (pt) Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c
TWI688385B (zh) 治療低血壓之方法
CN104321074B (zh) 生长抑素类似物与11β‑羟化酶抑制剂的组合
WO2013184621A1 (en) Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
US20250281470A1 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
CA3122581A1 (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
AU781842B2 (en) Use of growth hormone (hGH) for the treatment of sexual functional disturbances
Nicholson et al. Stress response during surgery
WO2006108667A2 (en) Method of treatment using gh antagonist and somatostatin agonist
US20160354444A1 (en) Compositions and methods for the treatment of sexual dysfunction
US20090062246A1 (en) Therapeutic treatment-014
WO2025117962A1 (en) Compositions and methods for treating glucose-dependent insulinotropic peptide-dependent cushing's syndrome
Walker ENDO 2018-100th Annual Meeting and Exposition of the Endocrine Society. Chicago, Illinois, USA-March 16-20, 2018
Pratap et al. Cessation of galactorrhea in a chronic kidney disease patient with non-tumoral hyperprolactinemia after renal transplantation
US20030207811A1 (en) Method of treating retinopathy of prematurity using somatostatin analogs
HK40034973A (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
JP2022551672A (ja) 乳癌治療法
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
Yuen Factors that Affect the Dosing Regimen of Growth Hormone Replacement Therapy in Adults with Growth Hormone Deficiency

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant